4th Annual India Leadership Conclave & Indian Affairs Business Leadership Award 2013 Nominations Announced

4th Annual India Leadership Conclave & Indian Affairs Business Leadership Award Nominations Announced

150 Nominees Make It To The 30 Top Categories, Among 7 Special Popular Juries Awards Include Veterans Ratan Tata, Mukesh Ambani, Priyanka Chopra,Manish Malhotra,DrMukesh Hariawala,Dr Mukesh Batra.

Maharashtra, Mumbai, Monday,1^st April 2013 : The much awaited & prestigious 4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards Nominations (www.indialeadershipconclave.net/2013 ) Finalists 2013 are announced today with votings line open organized by Indian Affairs, Asia’s biggest title in News Analysis (www.indianaffairs.tv ) from the illustrious Network 7 Media Group in association with Pharmaleaders, Breakfastnewstv,Pharmanewsprwire. Asia’s premier Event currently in 4^th year of its title received as many as 1700 Nominations from various verticals in the Nomination categories will host its 4^th Annual Affair in the commercial city of India, Mumbai on Friday 21^st June in a suburban hotel under the theme “New India – Hopes, Aspirations & Changing Outlook 2013. – Agenda for Change –’’. The last three editions which received widespread appreciations for its significant debating point were held at Delhi, Mumbai & Bangalore respectively. Widely perceived by the Industry Analysts as a vibrant platform of serious debate, The Conclave will witness more than 300 top business tycoons, Social Reformers, Bureaucrats & Policy makers.

Announcing the Final Nominations, Satya Brahma, Chairman & Editor-In-Chief of Network 7 Media Group said “India Leadership Conclave & Indian Affairs Business Leadership Awards organized by Network7 Media Group’s Indian Affairs Magazine, Asia’s biggest analytical news Magazine, arguably is one of India’s prestigious & coveted title & has established a credible platform of serious discussion where Brand India’s most illustrious Leaders & icons assemble to discuss the roadmap for India’s growth trajectory. The last three Annual Affairs has witnessed some of the biggest think-tanks of the contemporary leaders in society from social to political, from business to cultural, addressed, deliberated & opened up the new mantras of developments. While more than 100 Leaders of Indian mainstream polity have spoken, the platform has recognized & felicitated more than 300 Leaders & Enterprises. Indian Affairs Business Leadership Awards are set of prestigious awards developed by the Juries & bestowed to the deserving Leaders & Enterprises after a through screening of their landmark achievements for their significant accomplishments in their own fields under tough conditions imbibing innovation in their business approach. Clearly India Leadership Conclave & Indian Affairs Business Leadership Awards 2013 are India’s most eagerly awaited & prestigious title in recent times”. This Year’s Nominations has inclusion of some new categories such as Rising Brand Campaign Of The Year 2013, Brand Icon of The Year 2013, Corporate Governance & Sustainability Vision Award 2013 etc to make it much more wider & value-centric said Satya Brahma.

The Companies & Individuals who made it to the top five final categories are

1. Business Leader of The Year

Nominees

1. Dr. K. Ravindranath,Chairman & Managing Director – Global Hospitals Group. ( Code 01)

2. Rajiv Bajaj,Vice Chairman & MD.Bajaj Capital Ltd. ( Code 02)

3. Nirmal Jain.Managing Director, India Infoline Ltd. ( Code 03)

4. Malvinder Mohan Singh, Chairman, Fortis Healthcare Ltd. ( Code 4)

5. Mr. Joseph Massey, Managing Director & CEO, MCX Stock Exchange Ltd. ( Code 05)

2. Businesswoman of the Year

Nominees

1. Dr. Jyotsna Suri, Chairperson & Managing Director, Bharat Hotels Limited Enterprise. ( Code 06)

2. Zoya Akhtar, Producer & Director, Indian Cinema. ( Code07)

3. Renuka Ramnath, Founder, Managing Director, Multiples Alternate Asset Management. ( Code 08)

4. Shikha Sharma, CEO & MD, Axis Bank Ltd. ( Code 09)

5. Priya Paul, Chairman. Apeejay Surrendra Park Hotels. ( Code10)

3. India’s Most Valuable 4 Wheeler Company of The Year.

Nominees

1. 1.       Volkswagen Passenger Cars.  (Code 11)
2. 2.       Toyota Motors Ltd. (Code 12)
3. 3.       Renault India Private Limited. (Code 13)
4. 4.       Maruti Suzuki India Limited. (Code 14)
5. 5.       Fiat Group Automobiles India Pvt. Ltd. ( Code 15)

4. India’s Most Valuable IT Software Company.

Nominees

1. 1.       Datamatics Global Services Limited. (Code 16)
2. 2.       Take Solutions Ltd. (Code 17)
3. 3.       First source Solutions Limited. (Code 18)
4. 4.       3i Infotech Ltd. (Code 19)
5. 5.       ABM Knowledgeware Ltd. (Code 20)

5. Outstanding Contribution to Skincare Innovation Award 2013.

Nominees

1. 1.       Dr. Rashmi Soni Lohiya, Head and consultant dermatologist, Cosmetologist.CEO, Dermatosurgeon, Skinsure Clinic. (Code 21)
2. 2.       Dr. Tripti Rathore,Master of Science Dermatology, MBBS,Clinical Director & Lead Dermatologist. ( Code 22)
3. Dr. Uday Preet Sidhu. Consultant Dermatologist & Cosmetologist. (Code 23)
4. Dr Nilayini. Consultant Dermatologist & Cosmetologist, Founder CEO, Blu skin and cosmetology clinic. (Code 24)
5. 5.       Dr Shuba Dharmana. Consultant Dermatologist, Hair Transplant Surgeon, Laser Specialist.CEO/Founder Dr.Shuba Skin & Laser Clinic. (Code 25)

 6.   Emerging Medical Equipment Company of the Year 2013

Nominees.

1. Avon Weighing Systems Limited. ( Code 26)

2. Contech Instruments Ltd. (Code 27)

3. Elder Instrument Pvt Ltd. (Code 28)

4. Preci-Tech Weighing Systems. (Code 29)

5. Mettler-Toledo India Private Limited. (Code 30)

7. CEO of the year.

Nominees

1. Puneet Chadda, CEO, HSBC Asset Management (India) Pvt Ltd. (Code 31)
2. Jayant Dua. MD & CEO, Birla Sun Life Insurance. (Code 32)
3. Mr. Arun Sawhney. CEO & Managing Director, Ranbaxy Ltd. (Code 33)
4. Mr.Upinder Zutshi. MD & CEO, Infinite Computer Solutions India Ltd. (Code 34)
5. Mr.Ishan Raina. CEO & Managing Director, Out of Home Media (India) Pvt. Ltd. (Code 35)

8. First Generation Entrepreneur of the year

Nominees

1. Virendra Mhaiskar. Chairman & MD, IRB Infrastructure Developers. (Code 36)
2. Prakash Guha. Managing Director. Zuventus Healthcare Ltd. ( Code 37)
3. Sachin Bansal and Binny Bansal. Flipkart.com. ( Code 38)
4. Sumant Sinha, Chairman & CEO, ReNew Power. ( Code 39)
5. Ram Chandra Agarwal. Founder Chairman,Vishal Retail.( Code 40)

9. Deal Maker of The Year 2013.

Nominees

1. 1.Copart inc. (Code 41)
2. 2.Flickpart.  ( Code 42)
3. 3.Via. (Code 43)
4. 4.Carwale. (Code 44)
5. 5.Yatra. (Code 45)

10. Emerging Company of the Year 2013 (Textiles)

Nominees

1.Sudar Industries Limited. ( Code 46)

2.Bombay Rayon Fashions Ltd. (Code 47)

3.Gokaldas Exports Limited (GEL). (Code 48)

4.Provogue (India) Limited. (Code 49)

5.Sutlej Textiles and Industries. ( Code 50)

11. India’s Valuable Financial Consultancy & Stock Brokerage Company 2013

Nominees

1.Angel Broking. (Code 51)

2.Edelweiss Group. ( Code 52)

3.Religare Securities Ltd. ( Code 53)

4.Kotak Securities. ( Code 54)

5.Bonanza Portfolio Ltd. (Code 55)

12. India’s Most Valuable Financial Legal Firm of the Year 2013

Nominees

1.Link Legal. (Code 56)

2.Khimji Kunverji & Co. (Code 57)

3.DSP Merrill Lynch Ltd. (Code 58)

4.DSK Legal. (Code 59)

5.J.Sagar Associates. (Code 60)

13.India’s Most Admired Beauty Expert (Medical Profession)

Nominees

1. Dr Rachita Dhurat. Cosmetic Dermatologist & Professor& Head in Dermatology LTM Medical College & LTMG Hospital. ( Code 61)

2. Dr. Rinky Kapoor. Consultant and Head – Department of Cosmetic Dermatology and Lasers – Fortis Hospitals, Mahim. (Code 62)

3. Dr.Jaishree Sharad. Cosmetic Dermatologist &CEO of Skinfiniti Aesthetic Skin and Laser Clinic, Vice President of the highly esteemed Cosmetic Dermatology. (Code 63)

4 .Dr. Rashmi Shetty. Cosmetic Dermatologist & leading expert for Non-Surgical Aesthetic Medicine in India. ( Code 64)

5. Dr Madhuri Agarwal. Cosmetic Dermatologist & Medical Head for West Region- Kaya Skin Clinic. ( Code 65)

14. India’s Most Valuable Company in Healthcare Innovations 2013

Nominees

1.Wanbury Ltd. (Code 66)

2.Aristo Pharmaceuticals Ltd. (Code 67)

3.Akumentis Healthcare Ltd. (Code 68)

4.Indoco Remedies Ltd. (Code 69)

5.Indchemie Health Specialities Pvt. Ltd. (Code 70)

15.India’s Emerging Healthcare Company of the Year 2013.

Nominees.

1.Wanbury Ltd. (Code 71)

2.Macleods Pharmaceuticals Limited. (Code 72)

3.Blue Cross Laboratories Ltd. (Code 73)

4.Wallace Pharmaceuticals Ltd. (Code 74)

5.Zuventus Healthcare Ltd. (Code 75)

16. Clinical Trials Data Management Company of The Year 2013.

Nominees

1.Quintiles India Ltd. (Code 76)

2 Clintrac International Private Limited. (Code 77)

3.Karmic Labs Pvt. Ltd. ( Code 78)

4.Semler Research Center. (Code 79)

5.Cytespace Research Private Limited . ( Code 80)

17. India’s Most Valuable Private Bank.

Nominees

1.Icici Bank Ltd. ( Code 81)

2.Axis Bank Ltd. ( Code 82)

3.Yes Bank Ltd. (Code 83)

4.Standard Chartered Bank. (Code 84)

5.Citi Bank NA. (Code 85)

18.India’s Most Valuable Public Bank.

Nominees

1.Bank of Baroda. ( Code 86)

2.State Bank of India. (Code 87)

3.IDBI Bank Ltd. (Code 88)

4.Punjab National Bank. (Code 89)

5.Oriental Bank of Commerce. (Code 90)

19. India’s Most Valuable Retail Electronic Company of the year.

Nominees

1.Reliance Digital Limited. (Code 91)

2.Croma (Infiniti Retail Limited ). (Code 92)

3.NEXT Retail India Ltd. (Code 93)

4.E-Zone ( Future Bazar Ltd). (Code 94)

5.Viveks Ltd. (Code 95)

20.India’s Most Reliable Payment Gateway Company 2013

Nominees

1.Itz Cash Card Ltd. ( Code 96)

2.E-BIlling Solution Pvt Ltd. (Code 97)

3.Avenues India Pvt Ltd. ( Code 98)

4.DirecPay. ( Code 99)

5.PayU Group. ( Code 100)

21. India’s Most Promising  B-School  of the Year 2013.

Nominees

1.Amity University. (Code 101)

2.The Indian School of Business. (Code 102)

3.The Indian Institute of Planning and Management. (Code 103)

4.Welingkar Institute of Management Development & Research. (Code 104)

5.Lal Bahadur Shastri Institute of Management & Technology. (Code 105)

22.India’s Emeging Healthcare Chain 2013.

Nominees

1.DM Healthcare. (Code 106)

2.Hinduja Healthcare Pvt. Ltd. (Code 107)

3.Radiant Life Care Pvt Limited. (Code 108)

4.Columbia Asia Hospitals. (Code 109)

5.Max Healthcare. (110)

23. India’s Most Promising Telecom Company of the Year 2013.

Nominees

1.Aircel.  ( Code 111)

2.Vodafone. (Code 112)

3.Airtel. (Code 113)

4.Uninor. (Code 114)

5.Reliance. (Code 115)

24. Rising Brand Campaign Of The Year 2013

Nominees

1.Made In India, A United Initiative. (Code 116)

2.India Brand Equity Foundation. (Code 117)

3.Interbrand ( Mudra Communications). (Code 118)

4.Lowe Lintas & Partner. (Code 119)

5.Campaign India (Haymarket Media India Ltd). (Code 120)

25. Brand Icon of The Year 2013.

Nominees

1.Kiran Bedi ( Social Reforms). (Code 121)

2.Virat Kohli ( Sports). (Code 122)

3.Katrina Kaif (Cinema). (Code 133)

4.Jaipal Ramesh (Politics). (Code 134)

5.Shailendra Singh (Branding & Communication). (Code 135)

26. Emerging Brand of The Year 2013

Nominees

1.Chericof Cough Series ( Ranbaxy). (Code 136)

2.Coalgate (Hindustan Lever Ltd.). (Code 137)

3.Coca-Cola (  Coca-Cola India Private Limited. (Code 138)

4.Nokia ( Nokia India Ltd). (Code 139)

5.Ponds. (Hindustan Unilever Limited). (Code 140)

27. India’s Most Valuable Company in Database Management. 

Nominees

1. Oracle India Private Limited. (Code 141)
2. Sybase Software India Pvt Ltd. (Code 142)
3. Datavail Infotech Pvt. Ltd. (Code 143)
4. Dataguru India Pvt Ltd. (Code 144)
5. Clover Infotech Pvt. Ltd. (Code 145)

28. Corporate Governance & Sustainability Vision Award 2013

Nominees

1.Mindtree Ltd. (Code 146)

2.Marg Ltd. (Code 147)

3.Power Grid Corpn. of India. (Code 148)

4.Hiranandani Constructions Pvt.Ltd. ( Code 149)

5.Aanjaneya Lifecare Ltd. (Code 11)

29. Social Enterprise of The Year 2013

Nominees

1. Samarthanam Trust for the Disabled   . (Code 146)

2. CRY (Child Rights and You) . (Code 147)

3. Trinayani. (Code 148)

4. Save The Children India. ( Code 149)

5. US Charities . (Code 150)

Special Categories

Individual Categories by Juries Verdict & Popular Choice ( No Votings)

1. 1.       Transformational Leader of the Decade. Ratan Tata, Chairman Emeritus of the Tata Group
2. 2.       Millennium Business Leader of the Decade,  Mr. Mukesh Dhirubhai Ambani, CMD, Reliance Industries Ltd.
3. 3.       Global Indian of The Year 2013 (Healthcare). Dr Mukesh Batra, Chairman, Dr Batra’s
4. 4.       Fashion Icon of The Year 2013 – Manish Malhotra, Fashion Designer.
5. 5.       Indian Healthcare Visionary of the Decade – Dr Mukesh Hariawala, Cardiac Surgeon & Healthcare Economist.
6. 6.       Actress of the Decade – Ms.Priyanka Chopra
7. 7.       Lifetime Achievement Award  : Prof. Dr. Nandkishore Shamrao Laud, Orthopaedic Surgeon, Chairperson, Laud Clinic.

Important Notification:

1. Nominations for 4^th Annual India Leadership Conclave & Business Leadership Awards 2013 voting starts on 1^st April 2013 to 17^th June 2013. www.indialeadershipconclave.net/2013
2. All Five Finalists are required to furnish details from time to time whenever the documents are required based on changing market conditions.
3. There are Five tier system of votings.
4. Vote By SMS : One can vote to any category by simply putting the Codes assigned to each Nominee. Xxxx to official Number 91 9036065456
5. Vote by Email . One can vote to categories such as Code Number Mentioned in the Website.For Example, 1234 to  myvote@indialeadershipconclave.net
6. The Organizers will conduct physical Interviews from the respective Category’s Target audience & the general public to count votes. This has been practice since all editions.
7. Online Votings in the Wewbsite at www.indialeadershipconclave.net/2013
8. Final Verdict by the Juries & Board Members.
9. The decision of the Juries is final & bindings to all categories.
10. Final Results will be announced on 21^st June, Friday, Hotel Lalit, Near Airport, Mumbai on the Award Night.
11. Special Categories Listed in Nomination Form need no Votings.
12. Only One vote by one person will be counted in both SMS as well as Email. Duplicate/Repeat votings will be rejected.
13. No need to Wite (Codes) while sending SMS Votings. Example Type 1234 Send To 919036065456
14. Standard Charges apply from any network, No additional charges as these are not commercial in nature.
15. 40 % Weightage will be given to Winner generated fron Public Votings via SMS & Emails. The Remaining 60 % will be on the Merits & Credentials as stipulated in Nomination Form.

Websites For Three Consecutive Conclaves can be seen at www.ilcbusinessleaders.com www.indialeadershipconclave.com www.indialeadershipconclave.net . Official Website for 2013 Nominations is www.indialeadershipconclave.net/2013

For Registrations, Please Contact :

India Leadership Conclave Secretariat

Unit No. 53, 2nd Floor,

Aditya Indistrial Estate,

Devrukhkarwadi, Chincholi Bunder,

Malad (W), Mumbai – 400 064

Phone: + 91 22 4248 1240 / 4248 1234 / 4248 1235

info@indialeadershipconclave.net

Aanjaneya Lifecare Set To Join Hands With Japanese Pharma Major For Breakthrough Anti-Malarial Molecule for Collaborative Research & Co-Marketing

Aanjaneya Lifecare Set To Join Hands With Japanese Pharma Major For Breakthrough Anti-Malarial Molecule for Collaborative Research & Co-Marketing

Financial Muscle To Be Robust With Foreign Currency Convertible Bonds – Dr Kannan Vishwanath, MD, Aanjaneya Lifecare Ltd.

Mumbai, Maharashtra, India. 6^th March 2013. Around 80 per cent of new drugs are brought to market by the big global majors, even though only 35 per cent of these have been developed by them from the earliest stage. Smaller companies engaged in research often find going the full course up to the market beyond their means and end up out-licensing their NCEs to the big pharmas. India, the country most affected by malaria in the South East Asian region, is projected to see a decrease of 50-75 per cent in malaria case incidence by 2015, a report by the World Health Organization said. The WHO's World Malaria Report 2012 said a concerted effort by endemic countries, donors and global malaria partners during the past decade has led to strengthened malaria control around the world. It however warned that a significant slowdown in global funding. Mumbai-based Aanjaneya Lifecare Limited Aanjaneya Lifecare having a significant presence in this segment, is the world’s third-largest manufacturer of quinine salts and the second-largest in India. Only nine companies globally manufacture quinine salts. Aanjaneya is only the second company to receive WHO prequalification for its anti-malarial APIs and formulations, is inching closer to a breakthrough research in the form of a Molecule in Research Partnership for collaborative marketing with a leading Japanese Pharma Major. If sources are tobe believed than the that the drug which has a 10 tears of Research  could cure all strains of malaria with a single oral dose and also block transmission of the deadly parasite from person to person. It may be noted here that Of the four major types of malarial parasites, it is plasmodium falciparum, carried by the female anopheles mosquito, which causes about 90 per cent of the malaria deaths. Synriam, is intended to combat falciparum malaria, has two major advantages over other drugs like chloroquine. Its dosage regimen is just one tablet for three days, while other drugs have to be taken twice or four times a day for three or more days. Interestingly Ranbaxy worked for a revolutionary Drug with Research going for 15-years of drug discovery. Cipla is also a leading player in this market. With this partnership, Aanjaneya Lifecare which is a leading supplier to most of the Indian Companies will look forward for a better deal in doing business in india. With a significant market presence with manufacturing and marketing capabilities in APIs (Active Pharmaceutical Ingredients) with focus on anti-malarial, and finished dosage forms (FDFs) , Aanjaneya Lifecare could fetch a bigger fortune as anti-malarial drugs market in india  is growing at  ~25% & Anti-malarial market size in India is estimated at Rs600 crore. The Company is yet to enter into domestic branded formulation market, though it has plans to start the fiercely competitive Indian market operation by early 2013.

Dr Kannan Vishwanath, Vice Chairman & Managing Director of Aanjaneya Lifecare Ltd in an exclusive interview to Satya Brahma, Editor-In-Chief of Pharmaleaders Group spoke on wide gamut of business & expansion plans including the decline of share prices due to tough market conditions. Aanjaneya Lifecare Ltd stock was trading at Rs.299.80, down by Rs.15.75 or 4.99%. The stock hit an intraday high of Rs.299.80 and low of Rs.299.80.The total traded quantity was 213 compared to 2 week average of 21517.

1.       According to data available with the stock exchanges, shares of Core Projects tumbled 62 per cent and was the biggest loser on the entire BSE, while scrips of Aanjaneya Lifecare, Sudar Inds, Flexituff, ABG Shipyard, Welcorp and Gemini Comm crashed by 20 per cent each. Any Specific Reasons?

Answer: If you look at the overall scenario, you will get a clear indication that some of the biggest Midcaps have been losing grounds primarily because of the toughest market conditions & Aanjaneya Lifecare is not an exception. We are definitely disturbed as trading in stock exchange has become challenging but this is a temporary phase, we have a strong growth plans & we are gearing for top gear with our ambitious plans. The Board of Directors of Aanjaneya Lifecare Ltd at its meeting held on March 05, 2013, have decided that the date of opening of issuance of FCCB up to USD 75 million is on March 12, 2013. Of late, we find a huge fluctuation in the market prices of our scrip and it is disturbing for us. In order to achieve the growth plans of the Company, we are in dialogue with our International Bankers for raising resources for the expansion through FCCB. The international investors are cautious due to wide fluctuation in the market price of our scrip."

2.       The S&P BSE mid-cap index fell by 1.20 per cent and S&P BSE small-cap index lost 1.36 per cent.What are the reasons for this decline?

Answer: As explained earlier, this is a volatile market conditions in all S&P BSE mid-cap index. You can’t expect healthier trading every day. Please look at our performances in our Annual Report, we have outpaced industry standards. While it will take sometimes to gain the momentum, we are confident of good numbers. No need for Investors to be panic. Investors can be assured of their returns as they have been getting earlier. Global Market volatility is also one of the factor. The midcap universe came under pressure largely on account of concerns about their earnings as some of them have reported Q3 numbers, which came below market expectations.

3.       While your Net profit declined by 13.9 per cent to Rs.10.45 crore from Rs.12.14 crore, though its net sales increased sharply by 35.6 per cent to Rs.145.86 crore from Rs.107.58 crore. What is your expectations from the next quarter?.

Answer: Please look at our announcement which is much healthier. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. The Company has reported a growth in the total Sales to the extent of 35.58% at Rs 1458.64 million during the third quarter ended 31st December 2012 compared to Rs 1075.78 million during the same period last year. The net profits for Q3 amounted to Rs 104.53 million as against Rs 93.37 million for the previous quarter ended 30th September 2012 and Rs 121.42 million for the corresponding period of previous year ended 31st December 2011. We will have a bigger chunk in next quarter though I can’t specify the numbers, it will definitely be bigger.

4.       Aanjaneya Lifecare has been a dark horse in Pharma Scrips since its IPO in 2009 as it has been consistently performing. Why there is a sudden fall?

Answer: As I have mentioned in my earlier note, we have a sound financials with a robust processs mechanism. Our Corporate Governance is our biggest strength. We have no huge debtors like other Pharma Companies. We have recorded good performance in a difficult period and the future is bright. We are seeing a promising period for the company one in which we could achieve our goals set towards customer satisfaction, quality standards and of course shareholder value. We will keep the growth momentum focused & visible. Coming Days will spell out our success in overseas markets.

5.       Do you have any overseas creditors as speculations are that you may have pressure to pay off?.

Answer : There are no such overseas creditors except our domestic vendors who import machineries from abroad.

6.       What are your expectations on the normalcy to prevail & bring back Investors confidence?.

Answer:  As you will be aware that Aanjaneya Lifecare Limited has got approval to issue Foreign Currency Convertible Bonds to eligible foreign investors amounting Rs.405 crore. We are working on the modalities & soon some positive news will come as I cant divulge more details at this point of time.

7.       What is your take on Union Budget 2013 & how Pharma sector has been represented?

Answer. The Entire Indian Inc has welcomed Finance Minister’s Budget on a positive note & Aanjaneya can say that Chidambaram had a tough task to meet. FM has gone by reforms & Prudence & not by Populism. ThoughAanjaneya  would have been happier if FM would have announced some landmark decisions. However, it has a ambitious direction. An industry that has grown from being fully dependent on foreign companies a few decades ago to being an indigenous entrepreneur-driven industry with over Rs 64,000-crore market today, an industry that has over 10,000 small and medium enterprises and about 300 large enterprises all over India, an industry that provides over 64,000 safe and efficacious medicines at affordable prices, an industry that provides employment to over 40 lakh people, an industry that has contributed significantly in improving the standard of life and life expectancy, bringing down the death rate and infant mortality rates etc. of our people, an industry that our Government is very proud to showcase to the world as ‘Pharmacy of the World’, an industry that has earned the respect, admiration and dependence of all countries of the world for providing safe, efficacious, affordable quality medicines – has been completely ignored in the Budget as pointed out by Secretary General of Indian Drug Manufacturers Association, Mr Daara Patel.. The pharmaceutical industry has been facing problems of huge CENVAT accumulation due to the inverted duty structure resulting in blockage of working capital and affecting competitiveness in international market and this needed to be addressed urgently. Considering the long-term benefits of R&D to the economy at large, all excisable goods used for R&D purposes should have been exempted from excise duty as also import of all capital goods to boost our R&D activities to produce and provide our people with the latest more therapeutic medicines, exemption of physician samples from central excise duty, and reduction of customs duty on all life-saving drugs, etc.The Indian pharma industry has always responded to the urgent calls of pharma Government, both in Centre and in States, in times of disaster and natural calamities by providing free medicines anywhere in India, without minding the production costs and expenses involved in reaching the medicines to those affected victims. It is sad that despite our repeated requests and representations, the Government continues to tax these voluntary free medicines by imposing excise duty and sales tax on them. It has been a very lopsided budget, in that investment allowance @ 15 per cent has been allowed to manufacturing companies that invest more than Rs 100 crores in plant and machinery in the next two years. Most of the manufacturing industries in India are small scale driven, with even our Prime Minister calling them ‘engines of growth’. How many companies can invest ‘more than Rs 100 crores’? It effectively blocks the lakhs of MSME units in India, not to mention over 10,000 units in the pharma industry from availing of this benefit. The 12th Five Year Plan in the report on MSME sector states that it is the “major base of manufacturing sector in India, with its contribution of over 45 per cent in the overall industrial output and calls for “substantial enhancement of plan allocation for the sector during the 12th Plan to address major bottlenecks facing the sector.”

No wonder many in the Indian pharma industry now feel that it is a futile exercise to spend time and effort providing our pre-Budget proposals for drafting the Union Budget year-after-year, as the Finance Ministry has been ignoring the industry time and again in the last few budgets.

8.       Experts see Markets  may see consolidation, Q3 results to set tone& Stock markets are expected to see some consolidation this week amid traders expected to closely track the next batch of quarterly results. What is your take on this?.

Answer: Yes very true, the Market is going to be robust & Q3 results will be better for most of the Pharma Companies who are performing well. As far as Aanjaneya Lifecare is concerned, We are sure to cross the good numbers.

9.       Market is abuzz with speculation that Aanjaneya Lifecare is inching closer to a Japanese Drug Maker for a Collaborative Breakthrough in Anti-Malaria Segments to produce & Market Drugs in your Pune Facilty. Can you explain more on this?.

Answer: I have been getting this news from the market & from media reports ever since a delegation of pharmaceutical firms from Japan's Toyama prefecture indicated few days back while they were in india that Japanese companies were keen to collaborate with Indian pharma companies in trade and technology development. Toyama, which is recognized as the cluster city of pharmaceutical industry in Japan, has around 100 companies. Japanese Delegation had said that they were  looking for long term partnerships with Indian companies. There is immense scope of exporting Japanese products to Indian market and similarly Indian products can be traded in the Japanese market,". And I think, I think it is too early to speculate on meetings with Japanese Companies.

10.   The Deal is widely perceived that you may be the First one to tie up with a Japanese Firm to give you market access to Regulated Market. Is this True??

I can’t speculate on media reports. I am neither denying nor announcing anything. It is true that Aanjaneya Lifecare has plans to enter into the regulated markets, but we can’t comment on any developments as there is nothing to share as of now.